Cancer Pain - Pipeline Review, H2 2016

Date: November 23, 2016
Pages: 157
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C2B24D162B9EN
Leaflet:

Download PDF Leaflet

Cancer Pain - Pipeline Review, H2 2016
Cancer Pain - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cancer Pain – Pipeline Review, H2 2016, provides an overview of the Cancer Pain (Central Nervous System) pipeline landscape.

Cancer pain can be defined as a complex sensation that reflects both damage to the body and the body's response to the damage. Pain may arise due to tumor compressing or infiltrating tissue, from treatments and diagnostic procedures, or from skin, nerve and other changes caused by either the body's immune response or hormones released by the tumor. Cancer pain can be treated by analgesic drug therapy, non-opioid analgesics, opioid analgesics, adjuvant drugs, psychotherapy, anesthetic and neurosurgical pain management.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cancer Pain – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Cancer Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cancer Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cancer Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 8, 5, 3, 19, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.Cancer Pain.

Cancer Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cancer Pain (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Cancer Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cancer Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cancer Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cancer Pain (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cancer Pain (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cancer Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Cancer Pain Overview
Therapeutics Development
Pipeline Products for Cancer Pain - Overview
Pipeline Products for Cancer Pain - Comparative Analysis
Cancer Pain - Therapeutics under Development by Companies
Cancer Pain - Therapeutics under Investigation by Universities/Institutes
Cancer Pain - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Cancer Pain - Products under Development by Companies
Cancer Pain - Products under Investigation by Universities/Institutes
Cancer Pain - Companies Involved in Therapeutics Development
Alexza Pharmaceuticals Inc
AngioChem Inc
Aoxing Pharmaceutical Company Inc
Aphios Corp
AstraZeneca Plc
Benitec Biopharma Ltd
BioDelivery Sciences International Inc
ChironWells GmbH
Colby Pharmaceutical Company
Daiichi Sankyo Company Ltd
Dompe Farmaceutici SpA
Fujimoto Pharmaceutical Corp
Grunenthal GmbH
GW Pharmaceuticals Plc
Hisamitsu Pharmaceutical Co Inc
Immupharma Plc
IntelGenx Corp
iX Biopharma Ltd
Kancera AB
Klaria Pharma Holding AB
Komipharm International Co Ltd
KPI Therapeutics Inc
Neurocentrx Pharma Ltd
Nippon Kayaku Co Ltd
Orion Oyj
Pain Therapeutics Inc
Pfizer Inc
Pharmaleads SA
Recordati SpA
Ribomic Inc.
Trillium Therapeutics Inc
Virobay Inc
WEX Pharmaceuticals Inc
Zynerba Pharmaceuticals Inc
Cancer Pain - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ANG-2002 - Drug Profile
AQU-118 - Drug Profile
AZD-8797 - Drug Profile
BBI-11008 - Drug Profile
buprenorphine hydrochloride - Drug Profile
cebranopadol - Drug Profile
CPC-111 - Drug Profile
crotalphine - Drug Profile
CSTI-200 - Drug Profile
dexmedetomidine hydrochloride - Drug Profile
dronabinol - Drug Profile
Drug 1 for Migraine and Cancer Pain - Drug Profile
Drug 2 for Migraine and Cancer Pain - Drug Profile
Drug 3 for Migraine and Cancer Pain - Drug Profile
Drug for Cancer Neuropathic Pain - Drug Profile
Drug for Migraine and Cancer Pain - Drug Profile
fentanyl - Drug Profile
fentanyl citrate - Drug Profile
fentanyl citrate - Drug Profile
fentanyl citrate - Drug Profile
fentanyl citrate ER - Drug Profile
gabapentin - Drug Profile
HP-3150 - Drug Profile
HS-198 - Drug Profile
hydromorphone hydrochloride - Drug Profile
HYLP-002 - Drug Profile
INT-0010 - Drug Profile
IPP-102199 - Drug Profile
methadone hydrochloride - Drug Profile
nabiximols - Drug Profile
Nervarna - Drug Profile
PAX-1 - Drug Profile
Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain, Fibromyalgia, Inflammatory Pain and Neuropathic Pain - Drug Profile
Peptide to Target CANP for Cardiovasclar and Cancer Pain - Drug Profile
PL-265 - Drug Profile
QX-314 - Drug Profile
RBM-004 - Drug Profile
RBM-007 - Drug Profile
resiniferatoxin - Drug Profile
saracatinib difumarate - Drug Profile
Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile
Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile
Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile
Small Molecules for Pancreatic Cancer and Perineural Invasion - Drug Profile
tanezumab - Drug Profile
Tetrodotoxin - Drug Profile
tilidine hydrochloride - Drug Profile
U-2902 - Drug Profile
VBY-825 - Drug Profile
zucapsaicin - Drug Profile
ZYN-001 - Drug Profile
Cancer Pain - Dormant Projects
Cancer Pain - Discontinued Products
Cancer Pain - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 153

LIST OF TABLES

Number of Products under Development for Cancer Pain, H2 2016
Number of Products under Development for Cancer Pain - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2016
Cancer Pain - Pipeline by Alexza Pharmaceuticals Inc, H2 2016
Cancer Pain - Pipeline by AngioChem Inc, H2 2016
Cancer Pain - Pipeline by Aoxing Pharmaceutical Company Inc, H2 2016
Cancer Pain - Pipeline by Aphios Corp, H2 2016
Cancer Pain - Pipeline by AstraZeneca Plc, H2 2016
Cancer Pain - Pipeline by Benitec Biopharma Ltd, H2 2016
Cancer Pain - Pipeline by BioDelivery Sciences International Inc, H2 2016
Cancer Pain - Pipeline by ChironWells GmbH, H2 2016
Cancer Pain - Pipeline by Colby Pharmaceutical Company, H2 2016
Cancer Pain - Pipeline by Daiichi Sankyo Company Ltd, H2 2016
Cancer Pain - Pipeline by Dompe Farmaceutici SpA, H2 2016
Cancer Pain - Pipeline by Fujimoto Pharmaceutical Corp, H2 2016
Cancer Pain - Pipeline by Grunenthal GmbH, H2 2016
Cancer Pain - Pipeline by GW Pharmaceuticals Plc, H2 2016
Cancer Pain - Pipeline by Hisamitsu Pharmaceutical Co Inc, H2 2016
Cancer Pain - Pipeline by Immupharma Plc, H2 2016
Cancer Pain - Pipeline by IntelGenx Corp, H2 2016
Cancer Pain - Pipeline by iX Biopharma Ltd, H2 2016
Cancer Pain - Pipeline by Kancera AB, H2 2016
Cancer Pain - Pipeline by Klaria Pharma Holding AB, H2 2016
Cancer Pain - Pipeline by Komipharm International Co Ltd, H2 2016
Cancer Pain - Pipeline by KPI Therapeutics Inc, H2 2016
Cancer Pain - Pipeline by Neurocentrx Pharma Ltd, H2 2016
Cancer Pain - Pipeline by Nippon Kayaku Co Ltd, H2 2016
Cancer Pain - Pipeline by Orion Oyj, H2 2016
Cancer Pain - Pipeline by Pain Therapeutics Inc, H2 2016
Cancer Pain - Pipeline by Pfizer Inc, H2 2016
Cancer Pain - Pipeline by Pharmaleads SA, H2 2016
Cancer Pain - Pipeline by Recordati SpA, H2 2016
Cancer Pain - Pipeline by Ribomic Inc., H2 2016
Cancer Pain - Pipeline by Trillium Therapeutics Inc, H2 2016
Cancer Pain - Pipeline by Virobay Inc, H2 2016
Cancer Pain - Pipeline by WEX Pharmaceuticals Inc, H2 2016
Cancer Pain - Pipeline by Zynerba Pharmaceuticals Inc, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Cancer Pain - Dormant Projects, H2 2016
Cancer Pain - Dormant Projects (Contd..1), H2 2016
Cancer Pain - Dormant Projects (Contd..2), H2 2016
Cancer Pain - Dormant Projects (Contd..3), H2 2016
Cancer Pain - Discontinued Products, H2 2016 145

LIST OF FIGURES

Number of Products under Development for Cancer Pain, H2 2016
Number of Products under Development for Cancer Pain - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Cancer Cachexia - Pipeline Review, H2 2016 US$ 2,000.00 Jul, 2016 · 108 pages

Ask Your Question

Cancer Pain - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: